Poseida Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
06/08/2024 13:00
* Poseida Therapeutics Inc PSTX.OQ reported a quarterly
adjusted
loss of 32 cents per share for the quarter ended in June,
identical to the same quarter last year. The mean expectation
of five analysts for the quarter was for a loss of 41 cents per
share. Wall Street expected results to range from -47 cents
to -35 cents per share.
* Revenue rose 29.8% to $25.97 million from a year ago;
analysts
expected $15.43 million.
* Poseida Therapeutics Inc's reported EPS for the quarter
was a
loss of 32 cents.
* The company reported a quarterly loss of $31.37 million.
* Poseida Therapeutics Inc shares had risen by 3.4% this
quarter and lost 10.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 5.8%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Poseida
Therapeutics Inc is $12.00
This summary was machine generated from LSEG data August 6 at
12:00 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.41 -0.32 Beat
Mar. 31 2024 -0.42 -0.25 Beat
Dec. 31 2023 -0.39 -0.27 Beat
Sep. 30 2023 -0.29 -0.35 Missed